ARKG ARK Genomic Revolution ETF
CBOEETFAs of 2026-10-08 16:00
Why ARKG matters now
ARK Genomic Revolution ETF (ARKG) is a US etf in Financial Services. The latest InvestLog snapshot shows $49.29 with -1.70% on the session and $1.72B in assets/market value.
The latest indexable market news headline is "Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You" from Benzinga.
ETF Profile
Updated 2026-10-09Net Assets
$1.56B
NAV
$50.11
Expense Ratio
0.75%
Holdings
10
Issuer
ARK
Asset Class
Equity
Avg Volume
3,961,566
Inception
2014-10-31
Sector Exposure
Top Holdings
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| TXG | 10X GENOMICS INC-CLASS A | 9.23% | $189.1M |
| TWST | TWIST BIOSCIENCE CORP | 8.55% | $175.3M |
| TEM | TEMPUS AI INC-CL A | 8.30% | $170.2M |
| CRSP | CRISPR THERAPEUTICS AG | 5.25% | $107.6M |
| ILMN | ILLUMINA INC | 4.78% | $97.9M |
| NTRA | NATERA INC | 4.71% | $96.5M |
| GH | GUARDANT HEALTH INC | 4.71% | $96.5M |
| ABSI | ABSCI CORP | 4.62% | $94.6M |
| CDNA | CAREDX INC | 4.14% | $84.9M |
| PSNL | PERSONALIS INC | 4.01% | $82.1M |
Latest News
Fund Info
Asset Type
ETF
Exchange
CBOE
Currency
USD
Issuer
ARK
Asset Class
Equity
NAV Currency
USD
The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.